Skip to main navigation
  • Contact Us
Xen 01
  • About Us
    • Management
    • Partnering
    • Board of Directors
  • Pipeline
    • Vudalimab (PD-1 x CTLA-4)
    • Plamotamab (CD20 x CD3)
    • XmAb564 (IL-2-Fc)
    • XmAb819 (ENPP3 x CD3)
    • XmAb808 (B7-H3 x CD28)
    • XmAb662 (IL12-Fc)
    • XmAb541 (CLDN6 x CD3)
  • Technology
    • Bispecific Fc Domains
    • Cytotoxic Fc Domains
    • Immune Inhibitor Fc Domains
    • Xtend Fc Domains
    • Publications
  • Clinical Trials
    • Expanded Access Policy
  • Investors
    • Investors
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Management
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • Corporate Responsibility
    • Financials & Filings
      • SEC Filings
      • Annual Reports
    • Analyst Coverage
    • Stock Information
      • Historic Stock Lookup
      • Investment Calculator
    • Investor FAQs
    • Contact Us
    • Email Alerts
  • Careers
    • Opportunities

You are here:
Home / Investors / Financials & Filings / Annual Reports

Investor Relations

  • Investors
  • Press Releases
  • Events & Presentations
  • Corporate Governance
  • Corporate Responsibility
  • Financials & Filings
    • SEC Filings
    • Annual Reports
  • Analyst Coverage
  • Stock Information
  • Investor FAQs
  • Contact Us
  • Email Alerts

Tools

Shareholder Tools

  • Snaphot
  • Print
  • Share
  • Facebook
  • LinkedIn
  • Twitter
  • RSS

Annual Reports

Date Title
Feb 27, 2023
Add Links to Pages
2022 Annual Report
Feb 24, 2022
Add Links to Pages
2021 Annual Report
Feb 24, 2021
Add Links to Pages
2020 Annual Report
Feb 25, 2020
Add Links to Pages
2019 Annual Report
Feb 26, 2019
Add Links to Pages
2018 Annual Report
Feb 28, 2018
Add Links to Pages
2017 Annual Report
Xencor © Copyright 2023 | Privacy Policy
Scroll to top